Health and Medicine
PUBLISHED
An early Phase 1b clinical trial for an Alzheimer’s disease vaccine has recruited its first patient, states vaccine developer Alzinova AB. The vaccine, called ALZ-101, contains antibodies that directly target neurotoxic build-ups of protein, amyloid-beta oligomers, that develop in Alzheimer’s patients and are thought to block important brain signaling.
The rest of this article is behind a paywall. Please sign in or subscribe to access the full content.These aggregations are found up to 20 years before developing the disease, and the hope is a vaccine that prevents them from forming in the brain may prevent the cognitive deficits and memory loss that arises with Alzheimer’s.
"It is very satisfying that ALZ-101 has now entered clinical testing in an area with such a huge unmet medical need. We are looking forward to continuing the development of this potential disease-modifying treatment with the long-term goal to treat and prevent the onset and progression of this devastating disease," says Kristina Torfgård, CEO of Alzinova AB, in a statement.
The trial will be double-blind, placebo-controlled, and randomized, the gold standard for an early Phase 1 trial such as this. Phase 1 trials are conducted to evaluate the safety and dosage of the experimental drug or vaccine, but this trial will also look to assess the immune response elicited by the vaccine.
